Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (Nasdaq: RIGL) has announced the granting of inducement awards under its Inducement Plan, as approved by the company's Compensation Committee. The grants, made in accordance with NASDAQ Listing Rule 5635(c)(4), consist of 46,131 stock options awarded to eight non-executive employees. These options will vest over a four-year period with a one-year cliff.
The awards were granted as material inducements for these employees entering into employment with Rigel. The company, founded in 1996 and based in South San Francisco, California, focuses on developing and providing novel therapies for patients with hematologic disorders and cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL) ha annunciato l'assegnazione di premi di indotto nell'ambito del suo Piano di Induzione, approvato dal Comitato di Remunerazione dell'azienda. I premi, concessi in conformità alla Regola di Quotazione NASDAQ 5635(c)(4), consistono in 46.131 opzioni azionarie assegnate a otto dipendenti non esecutivi. Queste opzioni matureranno nell'arco di un periodo di quattro anni con un periodo di cliff di un anno.
I premi sono stati concessi come incentivi materiali per questi dipendenti che entrano a far parte della Rigel. L'azienda, fondata nel 1996 e con sede a South San Francisco, California, si concentra sullo sviluppo e la fornitura di terapie innovative per i pazienti con disturbi ematologici e cancro.
Rigel Pharmaceuticals (Nasdaq: RIGL) ha anunciado la concesión de premios de inducción bajo su Plan de Inducción, aprobado por el Comité de Compensación de la empresa. Las concesiones, realizadas de acuerdo con la Regla de Cotización de NASDAQ 5635(c)(4), consisten en 46,131 opciones sobre acciones otorgadas a ocho empleados no ejecutivos. Estas opciones se otorgarán durante un período de cuatro años con un periodo de cliff de un año.
Los premios se concedieron como incentivos materiales para estos empleados al ingresar a trabajar en Rigel. La empresa, fundada en 1996 y con sede en South San Francisco, California, se centra en desarrollar y ofrecer terapias novedosas para pacientes con trastornos hematológicos y cáncer.
리겔 제약 (Nasdaq: RIGL)는 회사 보상 위원회의 승인을 받은 유도 계획에 따라 유도 상의 수여를 발표했습니다. 이 상은 NASDAQ 상장 규정 5635(c)(4)에 따라 시행되었으며, 46,131 주식 옵션이 여덟 명의 비임원 직원에게 수여되었습니다. 이 옵션은 1년의 클리프 기간과 함께 4년 동안 가득 차게 됩니다.
상은 이 직원들이 리겔에 입사하는 것을 위한 물질적 유도로서 주어졌습니다. 1996년에 설립되어 캘리포니아주 샌프란시스코 남부에 본사를 두고 있는 이 회사는 혈액 질환 및 암 환자를 위한 혁신적인 치료법 개발과 제공에 주력하고 있습니다.
Rigel Pharmaceuticals (Nasdaq: RIGL) a annoncé l'octroi de récompenses d'incitation dans le cadre de son Plan d'Incitation, approuvé par le Comité de Rémunération de l'entreprise. Les attributions, effectuées conformément à la Règle d'Inscription NASDAQ 5635(c)(4), consistent en 46.131 options d'achat d'actions attribuées à huit employés non-exécutifs. Ces options seront acquises sur une période de quatre ans avec une période de cliff d'un an.
Les récompenses ont été accordées comme incitations matérielles pour ces employés qui entrent au service de Rigel. L'entreprise, fondée en 1996 et basée à South San Francisco, Californie, se concentre sur le développement et la fourniture de thérapies novatrices pour les patients atteints de troubles hématologiques et de cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL) hat die Vergabe von Anreizzahlungen im Rahmen seines Anreizplans bekannt gegeben, der vom Vergütungsausschuss des Unternehmens genehmigt wurde. Die Zuwendungen, die gemäß der NASDAQ-Notierungsregel 5635(c)(4) vergeben wurden, bestehen aus 46.131 Aktienoptionen, die an acht nicht-executive Mitarbeiter vergeben wurden. Diese Optionen werden über einen Zeitraum von vier Jahren mit einer einjährigen Cliff-Periode fällig.
Die Preise wurden als materielle Anreize für diese Mitarbeiter gewährt, die in die Beschäftigung bei Rigel eintreten. Das Unternehmen, das 1996 gegründet wurde und seinen Sitz in South San Francisco, Kalifornien, hat, konzentriert sich auf die Entwicklung und Bereitstellung neuartiger Therapien für Patienten mit hämatologischen Störungen und Krebs.
- Stock options grant indicates continued company growth and hiring
- Stock options may lead to future dilution of existing shareholders
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302341717.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
How many stock options did Rigel Pharmaceuticals (RIGL) grant in their January 2025 inducement awards?
What is the vesting schedule for RIGL's January 2025 inducement stock options?
How many employees received RIGL's January 2025 inducement grants?
Under which NASDAQ rule were RIGL's January 2025 inducement grants issued?
